Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study

Massimo Filippi; Elisabetta Pagani; Renato Turrini; Marta Bartezaghi; Vincenzo Brescia Morra; Giovanna Borriello; Valentina Torri Clerici; Massimiliano Mirabella; Livia Pasquali; Francesco Patti; Rocco Totaro; Paolo Gallo; Maria A. Rocca

doi:10.1007/s00415-024-12590-z

Related publications

Article2022

Transcriptional Effects of Fingolimod Treatment on Peripheral T Cells in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Massimo Filippi, Paolo Provero, Federica Esposito

Article2005

Progressive Gray Matter Damage in Patients With Relapsing-Remitting Multiple Sclerosis

Celia Oreja‐Guevara, Marco Rovaris, Giuseppe Iannucci, Paola Valsasina, Domenico Caputo, Rosella Cavarretta, Maria Pia Sormani, Pasquale Ferrante, Giancarlo Comi, Massimo Filippi

Article2021

Transcriptomic Analysis of Peripheral Monocytes upon Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients

Giacomo Sferruzza, Ferdinando Clarelli, Elisabetta Mascia, Laura Ferrè, Linda Ottoboni, Melissa Sorosina, Silvia Santoro, Lucia Moiola, Vittorio Martinelli, Gıancarlo Comı, Filippo Martinelli Boneschi, Massimo Filippi, Paolo Provero, Federica Esposito

Article2022

Early use of fingolimod is associated with better clinical outcomes in relapsing–remitting multiple sclerosis patients

Miryam Cannizzaro, Laura Ferrè, Ferdinando Clarelli, Antonino Giordano, Francesca Sangalli, Bruno Colombo, Gıancarlo Comı, Lucia Moiola, Vittorio Martinelli, Massimo Filippi, Federica Esposito

Article2017

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Lucia Moiola, Andrea Falini, Giancarlo Comi, Massimo Filippi